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linked immunosorbent assay kit.
Results:MeanserumKL-6 levels+/2 standarddeviation forBMTsub-
jects with BOS, BMT subjects without BOS and healthy controls were
571.6 +/2350.5, 302.3 +/287.3 and 209.1 +/277.6 U/ml, respectively.
The difference between BMT subjects with BOS and those without
BOS was statistically significant (p 5 0.003) as well as those with BOS
and healthy controls (p 5 0.001). There was no statistical difference
between BMT subjects without BOS and healthy controls (p5 .956).
Conclusions: KL-6 levels were significantly elevated in BMT sub-
jects with BOS as compared those without BOS and healthy controls.
KL-6 could serve as a diagnostic tool in detecting BOS in BMT
recipients.Table 1. Phase II Trial Clinical Outcomes
Clinical Outcome Incidence
Confidence
Interval
Cumulative Incidence of Grade II-IV aGVHD 13% (0.05-0.25)
Cumulative incidence of death without grade
II-IV aGVHD before day 100
13% (0.05-0.250)
Overall non relapse mortality 26% (0.16-0.41)
cGVHD 28% (0.17-0.43)
Relapse 17% (0.09-0.31)
TTP 4.4% (0.03-0.2)
CMV PCR 31% (0.19-0.45)
EBV PCR 20% (0.1-0.33)
HSV stomatitis & BK cystitis* 13% (0.06-0.26)
Bacterial infections 60% (0.45-0.73)
Oral candidiasis 6.7% (0.02-0.17)
SOS 6.7% (0.02-0.17)
*This incidence is for each of the the two viral infections.380
PERIPHERAL BLOOD STEM CELL TRANSPLANTATION VERSUS BONE
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Introduction: Severe Aplastic Anemia (SAA) is a rare disease and the
outcome of these patients has improved with hematopoietic stem cell
transplantation (HSCT). In patients who have anHLA-identical sib-
ling donor, HSCT is the preferred treatment. This is a retrospec-
tively study in patients who received bone marrow (BMT) or
peripheral blood stem cell transplantation (PBSCT) and compared
the differences in hematologic recovery, acute and chronic
GVHD, relapse and disease free survival and overall survival in
two groups.
Methods: Totally 173 patients with diagnosis of SAA between
March 1991 and October 2010, received allogeneic hematopoietic
stem cell transplantation from an HLA-identical sibling donor (167
patients) orHLA fullmatched other related donor (6 patients).Three
patients exclude from study because received both bone marrow and
peripheral blood.Median age in BMTgroup was 17 years (range 1 to
32 year) and in PBSCTwas 23 years (range 2 to 50 year). All patients
received the conditioning regimencontaining cyclophosphamide and
ATG as our center protocol and cyclosporine and methotrexate for
graft-versus-host disease (GVHD) prophylaxis.
Result: The median of follow-up was 40 and 20.5 month in BMT
and PBSCT group respectively. The median time to reach ANC $
500/mm3 and platelet $ 20000/ml in PBSCT group (11 and 17
days, respectively) was significantly lower than BMT group (16
and 19 days, respectively) (P\ 0.001). In two groups there was no
difference in the incidence of acute GVHD (p 5 1.0). The cumula-
tive incidence of chronic GVHD for those who survived more than
90 days was 10.2% in the BMT group, compared to 27% in the
PBSCT group (p 5 0.022). Relapse of disease occur in twelve
(24%) patients among BMT recipients and in 8 (6.5%) patients of
PBSCT recipients (p 5 0.005). Disease-free survival at 1 year was
74% in the BMT group and 86% in the PBSCT group (p 5 0.24)
and Overall survival at 1 year was 82% in the BMT group and
89% in the PBSCT group (p 5 0.8). Nine patients in BMT group
and 19 patients in PBSCT group were dead.
Discussion:However it seems that bone marrow is preferred source
for progenitor cell for SAA transplantation but this study results
showed that there was no difference in overall survival and disease
free survival in two groups. But engraftment was rapid in multi-
transfused patients who undergoing PBSCT than BMT with
significant differences.381
PHASE II TRIAL: THE COMBINATION OF TACROLIMUS, SIROLIMUS, AND
RABBIT ANTI-THYMOCYTE GLOBULIN (THYMOGLOBULIN THYMO) TO
PREVENT ACUTE GRAFT-VS.-HOST DISEASE (AGVHD) IN PATIENTS RE-
CEIVING UNRELATED HEMATOPOIETIC STEM CELL TRANSPLANTATION
(UHSCT)
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Background: Acute graft versus host disease continues to affect ap-
proximately 60% of patients undergoing UHSCT, with significant
mortality and morbidity.
Methods: We prospectively evaluated the efficacy of combining
Thymo (4.5 mg/kg divided doses on days -1,-2, and -3), Tacrolimus
and Sirolimus in preventing aGVHD. The cumulative incidence rate
at 100 days of grade II-IV aGVHDwas calculated using death without
grade II-IV aGVHD as competing risk. The median time to relapse,
defined as time from BMT to the event of relapse or death due to re-
lapse, was reported using KM method. The proportions of relapse,
non-relapse mortality, cGVHD, and incidence of infections were re-
ported with the Wilson’s 95% Confidence Interval (in table below).
Results: Between August 2008 and August of 2010, 45 patients (pts)
were enrolled, with median age of 53(20-70) years. The Median fol-
low-up time is 10.5 months (1.3-26.5). There were 20 AML, 11
MDS, 4 ALL, 2 CML, 1 CLL, 3 Myelofibrosis, 2 multiple myeloma,
2 NHL pts. Preparative regimens included Bu/Flu (29), Bu/Flu-TBI
(9), VP16/TBI (3), R-BEAM (1), and Flu/MEL-TBI (3). All pts re-
ceived peripheral blood stem cells mobilized with G-CSF. Median
CD34+ dose was 7.31x106 /kg (1.9-18.6). Twenty pts received 8/8
and 25 received 7/8HLAmatched grafts respectively. All patients’ en-
grafted,withmediandayof 12 (9-18).Sixteendeaths occurred through-
out the entire follow up period, due to: relapse (4), aGVHD (2),
cGVHD (3), sinusoidal obstruction syndrome (SOS) (1), bleeding
(1), multi organ failure (2), sepsis (2) and pneumonia (1). Eight patients
experienceddisease relapse.Twelvepatientshadnon-relapsemortality.
Thirteen pts developed aGVHD, 7 grade I, 3 grade II, 2 grade III,
and 1 grade IV. The cumulative incidence rate for grade II-IV
aGVHD at 100 days is 0.13 (0.053, 0.250); the cumulative incidence
rate of the competing event death without grade II-IV aGVHD at
day 100 is 0.13 (0.053, 0.250). Thirteen pts developed cGVHD.
There were 2 cases of thrombotic thrombocytopenic purpura
(TTP) before day 100. 14CMVby PCR, 9 EBV by PCR, 6HSV sto-
matitis, 6 BK cystitis, 27 bacterial infection, 3 oral candidiasis, and 3
SOS. The median time to relapse was 18.38 months.Conclusion: These early results suggest that the combination of
Thymo, Tacrolimus and Sirolimus in pts undergoing UHSCT is
well tolerated and is associated with a low rate and severity of acute
GVHD. Six months follow up data will be presented at the meeting.
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EFFECT OF RELATED AND UNRELATED DONOR HAEMATOPOIETIC STEM-
CELL TRANSPLANTATION ON OUTCOME IN ADULTS WITH HIGH RISK
HEMATOLOGICAL DISEASE: AN INTENTION-TO-TREAT ANALYSIS OF
410 PATIENTS AT A SINGLE CENTER INSTITUTION
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